TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1
The Journal of Pathology · 2026
DOI: 10.1002/path.70104 ↗At a glance
Journal article in The Journal of Pathology, 2026. Written by Agustina Jaroszewski and 20 co-authors. Institution: Centro de Investigaciones en Bioquímica Clínica e Inmunología. Consejo Nacional de Investigaciones Científicas y Técnicas. Departamento de Bioquímica…. Major MEDLINE topics: Hepatitis A Virus Cellular Receptor 2, Tumor Microenvironment, Transforming Growth Factor beta1, Thyroid Neoplasms. 50 references. Funded by: Fondo para la Investigación Científica y Tecnológica-Agencia Nacional de Promoción Científica y Técnica, Secretaría de Ciencia y Técnica (Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas.
Abstract (original language)
Thyroid cancer (TC) is the most common endocrine malignancy. While papillary thyroid cancer (PTC) generally has a favorable prognosis, anaplastic thyroid cancer (ATC) is rare but highly aggressive, with limited treatment options, highlighting the urgent need for novel therapeutic targets. Macrophages are a major component of the immune infiltrate in TC, and their abundance is associated with poor prognosis. We recently identified upregulation of the immune checkpoint TIM3 (T‐cell immunoglobulin and mucin‐domain containing protein 3) on M2‐like macrophages both in vitro and in ATC xenografts. In addition, we have shown that transforming growth factor β1 (TGFβ1) promotes macrophage polarization toward an M2‐like phenotype. However, the role and clinical significance of TGFβ1 in regulating TIM3 expression in TC‐associated macrophages remains unclear. We found that TGFβ1 secreted by ATC cells significantly increased HAVCR2 (TIM3) mRNA expression in human monocytes. Analysis of patient samples demonstrated elevated TIM3 expression in both PTC and ATC tissues compared with adenoma and normal thyroid counterparts. Analysis of publicly available single‐cell RNA sequencing datasets further showed increased TIM3 expression in T cells from both tumor types. Notably, TIM3 upregulation was also localized to M2‐like macrophages within the thyroid tumor microenvironment (TME), and positively correlated with TGFB1 / CD163 expression, suggesting the involvement of a TGFβ–TIM3 axis in macrophages in TC. Combined targeting of the TIM3 and PD1 pathway in an immunocompetent mouse model of ATC led to a significant reduction in tumor growth. Together, these findings highlight TIM3 as a promising immunotherapeutic target in TC, with the potential to suppress macrophage‐mediated pro‐tumor activity while enhancing T‐cell‐driven anti‐tumor immunity within the thyroid TME. © 2026 The Pathological Society of Great Britain and Ireland. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centro de Investigaciones en Bioquímica Clínica e Inmunología. Consejo Nacional de Investigaciones Científicas y Técnicas. Departamento de Bioquímica Clínica. Facultad de Ciencias Químicas, Universidad Nacional de Córdo…
- Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Instituto de Oncología Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina.
ORCID profiles: Wei Zhang, Laura Fozzatti
Funding
- Fondo para la Investigación Científica y Tecnológica-Agencia Nacional de Promoción Científica y Técnica
- Secretaría de Ciencia y Técnica (Universidad Nacional de Córdoba
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Florencio Fiorini Foundation Grant 2025
- Yamagiwa-Yoshida (YY) Study Grant
- National Scientific and Technical Research Council
Cite
APA
Jaroszewski, A., Choi, Y. S., Hellriegel, F., Zhang, W., Carrizo, F., Song, D. E., Laborie, M. V., Ruggieri, M., Peretti, E., Banus, M. V., Stempin, C. C., Nicola, J. P., Rodríguez, E. V. A., Day, C. P., Needle, G., Califano, I., Ramacciotti, C. F., Iglesias-Bartolome, R., Kim, W. G., …, & Fozzatti, L. (2026). TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1. The Journal of Pathology. https://doi.org/10.1002/path.70104
Vancouver
Jaroszewski A, Choi YS, Hellriegel F, Zhang W, Carrizo F, Song DE, et al. TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1. The Journal of Pathology. 2026. doi:10.1002/path.70104
BibTeX
@article{Jaroszewski2026,
author = {Jaroszewski, Agustina and Choi, Yeon-Sook and Hellriegel, Florencia and Zhang, Wei and Carrizo, Fernando and Song, Dong Eun and Laborie, María Victoria and Ruggieri, Marcelo and Peretti, Emiliano and Banus, María Victoria and Stempin, Cinthia Carolina and Nicola, Juan Pablo and Rodríguez, Eva Virginia Acosta and Day, Chi-Ping and Needle, Gabriel and Califano, Inés and Ramacciotti, Constanza Fernanda and Iglesias-Bartolome, Ramiro and Kim, Won Gu and Jeon, Min Ji and Fozzatti, Laura},
title = {TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1},
journal = {The Journal of Pathology},
year = {2026},
doi = {10.1002/path.70104}
}
EUVIMED